Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

Amgen (AMGN) and UCB announced that the U.S. Food and Drug Administration (FDA) has granted approval of Evenity™(romosozumab-aqqg) for osteoporosis in postmenopausal women at high risk for bone fracture. Evenity is different from all other osteoporosis products as it is a bone builder that increases bone formation and, to a lesser extent, reduces bone loss and, consequently, reduces the risk of fracture.

A full course of Evenity therapy is: 12 monthly doses administered . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.